Axial Therapeutics Presents Preclinical Data on Microbiome-Derived Metabolites Associated with Autism Spectrum Disorder October 18, 2019
Axial Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of AB-2004 for Treatment of Gastrointestinal Dysfunction and Associated Behavioral Symptoms of Autism Spectrum Disorder July 16, 2019
Axial Therapeutics Announces $10M Investment from Taiho Ventures to Access Axial’s Expertise in the Gut-Brain Axis June 24, 2019
Axial Therapeutics Announces Publication of Preclinical Data Highlighting the Link Between Human Gut Microbiota and Behavioral Symptoms of Autism Spectrum Disorder in Mouse Models May 31, 2019
Axial Therapeutics Releases New Preclinical Data from AB-2004 Program Demonstrating Reduction of Microbiome-Derived Metabolites in Mouse Models with Autism Spectrum Disorder May 2, 2019
